Ordering Recommendation

Use to assess genetic risk of abnormal drug metabolism for drugs metabolized by CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, and CYP3A5. May aid in drug selection and dose planning for many drugs. This test includes access to the GeneDose database; for testing that excludes GeneDose access, refer to Cytochrome P450 Genotyping Panel (3001524).

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Lavender (K2EDTA), pink (K2EDTA), or yellow (ACD solution A or B).

Specimen Preparation

Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Plasma or serum. Specimens collected in sodium heparin or lithium heparin. Frozen specimens in glass collection tubes.

Remarks
Stability

Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month

Methodology

Polymerase Chain Reaction (PCR) / Fluorescence Monitoring / Sequencing

Performed

Varies

Reported

5-10 days
If reflexed: 5-7 additional days are required for LR-PCR and sequencing.

Reference Interval

By report

Interpretive Data

Refer to report.

Couseling and informed consent are recommended for genetic testing. Consent forms are available online.

Compliance Category

Laboratory Developed Test (LDT)

Note

If long-range PCR/duplication testing is performed, additional charges will apply. Approximately less than 5% of samples require 2D6 copy number determination.

Hotline History

N/A

CPT Codes

81225; 81226; 81227; 81230; 81231; 81479; if reflexed, add 81479

Components

* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • CYP2B6
  • CYP2C cluster
  • CYP2C19
  • CYP2C8
  • CYP2C9
  • CYP2D6
  • CYP3A4
  • CYP3A5
Cytochrome P450 Genotyping Panel, with GeneDose Access